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Introduction
Gastrointestinal stromal tumor (GIST) is commonly characterized by mutations in the receptor tyrosine kinase genes KIT or platelet-derived growth factor receptor A (PDGFRA), leading to ligand-independent constitutive over-activation of signaling and subsequently increased understood. Identification of the pathways involved in imatinib resistance may facilitate the development of complementary therapeutic strategies to increase the effectiveness of imatinib.
We have previously identified a microRNA (miRNA), miR-125a-5p, that modulates imatinib response in GIST cells through regulation of protein tyrosine phosphatase non-receptor type 18 (PTPN18), a member of the PEST domain containing protein tyrosine phosphatase superfamily [5] . Protein tyrosine phosphatases, together with receptor tyrosine kinases, are key regulators of phosphorylation status and cellular signaling activities. The signaling activities are one of the major mechanisms for intra-and intercellular communication for cellular maintenance and disease-associated processes. PTPN18 can promote dephosphorylation of the HER2 receptor tyrosine kinase leading to inhibition of HER2-mediated signaling [6, 7] . In addition, increased HER2/PTPN18 ratio is associated with more advanced breast cancer stage [7] . These findings suggest a crucial role for PTPN18 as a negative regulator of signal transduction components and cancer progression.
Focal adhesion kinase (FAK) is one of the components of focal adhesion, which is the site of contact between the extracellular matrix and the cytoskeleton, and is important for signal transduction events. Several findings suggest the involvement of FAK in tumor progression and imatinib resistance of GIST. FAK over-expression is associated with tumor progression [8, 9] and poor overall survival [9] in GIST. Furthermore, FAK inhibition can induce apoptosis in GIST cells and decrease tumor size in mice [10] . Activation of FAK by phosphorylation (pFAK) was found higher in the imatinib-resistant GIST-T1-R subclones compared to imatinib-sensitive parental cells, and importantly, pFAK inhibition re-sensitizes the resistant cells to imatinib-induced cell death [11] . These observations support an important role of pFAK in imatinib resistance of GIST. However, whether pFAK expression is associated with imatinib resistance in clinical samples and how FAK activation occurs in imatinib-resistant GIST remain unknown.
In this study, we investigated pFAK as a downstream target of PTPN18 and its role in imatinib resistance. Indeed, we demonstrated that miR-125a-5p over-expression and PTPN18 suppression increased pFAK level in GIST cells. Blocking of FAK phosphorylation using a small molecule inhibitor could re-sensitize resistant GIST cells to imatinib treatment. In addition, we also evaluated the clinical significance of FAK and pFAK in imatinib resistance, tumor progression and patient outcome in GIST.
Methods

GIST tissue samples
In total, 28 snap-frozen tumor samples from 22 patients were included in the study (Supplementary Table 1 ). All patients had received neoadjuvant imatinib treatment prior to surgery. Detailed information about clinical characteristics, KIT and PDGFRA mutations status, imatinib response and follow-up has been reported for all cases in our previous study [5] . All samples were collected with informed consent and ethical approval, and were retrieved from the Karolinska University Hospital Biobank.
GIST882 cell line and imatinib-resistant subclones
The parental imatinib-sensitive GIST882 cell line, which harbors an activating KIT mutation (K642E), was kindly provided by Dr. Jonathan Fletcher at Brigham and Women's Hospital, Boston, MA [12] . Three imatinib-resistant GIST882R subclones (GIST882-R1, GIST882-R2 and GIST882-R4) were used. GIST882-R1 and GIST882-R2 were established in our previous study [5] , and GIST882-R4 was generated in this study using conditions previously described [5] . All cell lines were grown in RPMI 1640 media supplemented with 15% fetal bovine serum, 2 mM Lglutamine and 1% penicillin-streptomycin, and cultured at 37°C with 5% CO 2 .
Authentication of GIST882 cells was previously reported based on KIT mutation analysis, CD117 immunocytochemistry and short tandem repeat (STR) profiling [5, 13] . The relationship between the GIST882 parental cell line and the three GIST882R subclones was confirmed for the presence of the K642E mutation in KIT exon 13 by Sanger sequencing using previously described methodology [5] .
GIST882 and the three GIST882R subclones were characterized for expression of three established GIST markers (CD117/c-kit, ANO1/ DOG1 and CD34) by immunocytochemistry. Cells were trypsinized and washed with cold phosphate buffered saline (PBS). Cells (1 ×10 5 / 100 µL) were centrifuged to Superfrost™ Plus microscope slides (Thermo Scientific) at 800 rpm for 5 min in a Shandon Cytospin 3 centrifuge (Thermo Scientific). Slides were air-dried before fixation with 100 µL of 4% paraformaldehyde in PBS (USB Corporation, Santa Clara, CA, USA) for 8 min. 
Transfection of shRNAs, siRNAs and microRNA
The cloning of short hairpin RNA (shRNA) against human PTPN18 (target sequence: GAGGGACACAGCGACTACA) into the pcDNA3-U6M2 vector has been described in our previous study [5] . A total of 3 × 10 6 GIST882 cells were transfected with 2 µg of plasmid DNA containing shRNA against PTPN18 (shPTPN18) or vector control (shControl), 1 µM of short interfering RNAs (siRNAs) targeting PTPN18 (SI02759351 and SI02759358; Qiagen) or siRNA control (siControl; AllStars Negative Control siRNA; Qiagen), as well as with 100 pmol of pre-miR-125a-5p or pre-miR-CTR negative control (Life Technologies). All transfections were performed with Amaxa nucleofection system (Lonza AG, Basel, Switzerland).
Western blot analysis
Proteins were extracted from cultured cells and frozen tissues using NP-40 lysis buffer (Life Technologies, Carlsbad, CA, USA) supplemented with protease inhibitor (Complete protease inhibitor cocktail; Roche, Mannheim, Germany), 1 mM of phenylmethanesulfonyl fluoride (Sigma-Aldrich, St. Louis, MO, USA) and 1% phosphatase inhibitor cocktail 3 (Sigma-Aldrich). The lysates were quantified using Pierce™ BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Protein lysates (50 μg) were separated by Novex® 4-12% NuPAGE® Bis-Tris gels (Life Technologies), transferred to nitrocellulose membranes (Life Technologies), and blocked in non-fat milk (5%) or bovine serum albumin (5%) diluted in TBS with 0.5% Tween-20. Membranes were then incubated overnight at 4°C with primary antibodies anti-PTPN18 (#8311; Cell Signaling Technology, Danvers, MA, USA) at dilution 1:1000, anti-Phospho-FAK (Tyr397, #8556; Cell Signaling Technology) at 1:1000, anti-FAK (#610087; BD Biosciences, Franklin Lakes, NJ, USA) at 1:1000, anti-cleaved PARP (#ab32064; Abcam, Cambridge, UK) at 1:1100 or anti-Phospho-STAT3 (Tyr705, sc-7993; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 1:200. Anti-rabbit IgG-HRP (#626120; Invitrogen, Carlsbad, CA, USA) at dilution 1:3000 or antimouse IgG-HRP (#626520; Invitrogen, Carlsbad, CA, USA) at 1:10000 were used as secondary antibodies. Incubation with anti-GAPDH antibody (sc-47724; Santa Cruz Biotechnology) at 1:5000 was performed for normalization purposes. Detection was carried out using Novex ECL HRP chemiluminescent substrate reagent (#WP20005; Life Technologies). Immunoblots were quantified with Image Gauge v.4.0 software (FujiFilm Science Lab, Tokyo, Japan).
TaqMan reverse transcription quantitative PCR (RT-qPCR)
Total RNA was isolated using mirVana miRNA Isolation Kit (Life Technologies, Carlsbad, CA, USA) and used for quantification of miR125a-5p and RNU6B. cDNA was synthesized from 100 ng of total RNAs using TaqMan MicroRNA Reverse Transcription Kit and miR-125a-5p (ID002198) or RNU6B (ID001093) TaqMan microRNA assays from Applied Biosystems. RNU6B was used as a normalization control. All reactions were performed in triplicate.
Inhibition of FAK phosphorylation and cell viability assay
To evaluate the effect of pFAK inhibition on the expression levels of pFAK, FAK and cleaved PARP in imatinib-resistant subclones, 2 µM of FAK inhibitor 14 (hereafter referred to as FAKi; SML0837, Sigma) was added to the cells for 24 h prior to harvesting. For cell viability assays, four different concentrations of FAKi (0.1, 1, 5 and 10 µM) and 1 µM of imatinib were added to GIST882-R1, -R2 and -R4 cell lines for 24, 48 and 72 h, followed by measuring the cell viability using WST-1 colorimetric assay (#5015944001, Sigma). To determine the half maximal inhibitory concentration (IC 50 ) of FAKi in GIST882 cells, various concentrations (0.01, 0.1, 1.0, 2.5, 10, 20, 50 and 100 µM) of FAKi were added to GIST882 cells together with or without imatinib (0.1 µM) for 24 h before cell viability assay. To evaluate the effect of FAKi on miR125a-5p mediated imatinib resistance, GIST882 cells were transfected with Pre-miR-125a-5p or Pre-miR-CTR for 48 h, followed by treatment with or without 5 µM of FAKi in the presence or absence of 0.1 µM imatinib. All experiments were conducted in at least three technical replicates for each condition and repeated at least three times independently. Cell viability was determined by comparing the absorbance values of the samples after background subtraction (OD 440 -660 nm).
Statistical analysis
MS Office Excel 2007 (Albuquerque, NM, USA), GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) or Statistica 8.0 (StatSoft Inc., Tulsa, OK, USA) was used for all statistical tests. Paired student's t-test was performed to analyze transfection experiments. Comparisons between protein expressions among or between different tumor groups were carried out using one-way ANOVA or Mann Whitney U-test. Associations of clinico-pathological features with protein levels were evaluated using Fisher's exact test. Tumors were classified into groups with high or low expression based on median protein expression level. The interrelationship of protein expression levels with survival was studied using Kaplan-Meier plots, and significant differences between curves were evaluated using log-rank test. All P-values obtained in this study were 2-tailed, and P-values < 0.05 were considered as statistically significant.
Results
Silencing of PTPN18 and over-expression of miR-125a-5p increased pFAK levels
Here, we hypothesized that PTPN18 might regulate FAK phosphorylation, and that down-regulation of PTPN18 by miR-125a-5p overexpression in GISTs may lead to FAK activation by phosphorylation and cause subsequent imatinib resistance (Fig. 1a) . To test this hypothesis, we first evaluated the expressions of FAK and pFAK in GIST882 cells with and without silencing of PTPN18 using shRNA (shPTPN18). As shown in Fig. 1b , silencing of PTPN18 expression using shPTPN18 increased the pFAK level (~1.3-folds; P < 0.001), whereas the FAK level remained unchanged. To determine the specificity of PTPN18 regulation on FAK phosphorylation, we also evaluated the phosphorylation level of another protein, STAT3, which revealed that pSTAT3 levels were unaffected by PTPN18 silencing (Fig. 1b) . To further support the findings, we also silenced PTPN18 using two different siRNAs (namely siPTPN18 #1 and siPTPN18 #2). Consistently, silencing of PTPN18 expression with both siRNAs increased pFAK (~1.4-folds; P < 0.05 for both siRNAs), but not FAK expression (Fig. 1c) . To further determine whether pFAK expression could be regulated by PTPN18 targeting miRNA, we ectopically expressed miR-125a-5p and evaluated its effect on pFAK and FAK expressions. Concordant with the findings of PTPN18 silencing, we observed an increase of pFAK (~1.2-folds; P = 0.04), but not FAK expression, in cells over-expressing miR-125a-5p ( Fig. 1d and e) .
Increased pFAK levels in imatinib-resistant GIST882R subclones
We employed three independently established imatinib-resistant subclones of GIST882 (GIST882-R1, GIST882-R2 and GIST882-R4). First, all resistant subclones were validated to harbor the same homozygous KIT K642E mutation and expression of GIST markers CD117, DOG1 and CD34 as their parental GIST882 cells (Fig. 2a) . Next we quantified PTPN18, FAK and pFAK protein levels, as well as miR-125a-5p expression in GIST882 and GIST882R cells using Western blot and RT-qPCR analyses, respectively. In consistence with our previous study [5] , miR-125a-5p expression was higher, while PTPN18 was lower, in all three imatinib-resistant GIST882R subclones than GIST882 cells (Fig. 2b) . Additionally, pFAK expression was higher in the imatinibresistant GIST882R subclones compared to their parental cells (P < 0.05; Fig. 2c ). On the other hand, FAK expression was similar in imatinib-resistant and -sensitive cells (Fig. 2d) .
Blocking of FAK phosphorylation increased imatinib-induced apoptosis
To further investigate the role of pFAK in imatinib resistance, we blocked FAK phosphorylation in imatinib-resistant GIST882R cells using the FAK inhibitor 14 (FAKi), which is a small molecule inhibitor that specifically block FAK phosphorylation at the tyrosine 397 residue. We then evaluated the effect on imatinib-induced cytotoxicity using WST-1 assay and Western blot analysis of cleaved PARP expression (a marker for apoptosis). Indeed, we observed 0.7-fold reduction of pFAK expression in all three imatinib-resistant subclones upon treatment with FAKi (P < 0.01; Fig. 3a) . Blocking of FAK phosphorylation also increased the level of cleaved PARP by 2-4-folds (P < 0.05; Fig. 3b) , indicating an increase in apoptosis. Furthermore a drastic decrease of cell viability was observed at 24, 48 and 72 h in all three GIST882R subclones treated with 5 µM or 10 µM of FAKi (Fig. 3c) . Reduced cell viability was also observed for 1 µM FAKi in GIST882-R1 and -R2 subclones (Fig. 3c) .
Blocking of FAK phosphorylation could rescue the miR-125a-5p overexpression-mediated imatinib resistance
We first determined the IC 50 of FAKi in GIST882 cells with and without imatinib treatment. The results showed that the IC 50 was comparable in cells treated with 0.1 µM imatinib (IC 50 = 5.10 µM) or without imatinib treatment (IC 50 = 5.13 µM) (Fig. 4a) , indicating that there is no synergetic effect of imatinib in combination with FAKi. Based on these observations, we applied the IC 50 dosage (5 µM) for evaluating the effect of FAKi treatment in GIST882 cells. To assess whether blocking of FAK phosphorylation could reverse the effect of miR-125a-5p over-expression, we transfected GIST882 cells with premiR-125a-5p or pre-miR-CTR for 48 h and then treated the cells with and without FAKi in combination with imatinib for 24 h prior to cell viability assay.
Consistently, over-expression of miR-125a-5p increased pFAK level Fig. 1 . Effect of PTPN18 inhibition and miR-125a-5p over-expression on pFAK and FAK levels in GIST882 cells. a Schematic illustration of the hypothesis for miR125a-5p regulation of imatinib resistance in GIST. In imatinib-resistant cells, FAK phosphorylation is increased due to suppression of its phosphatase PTPN18 by miR125a-5p. b-d Western blot analysis was performed in GIST882 cells transfected with: 2 µg of plasmid DNA containing shRNA targeting PTPN18 (shPTPN18) or vector control (shControl) (b), 1 µM of siPTPN18 #1 and #2 or siControl (c), and 100 pmol of Pre-miR-125a-5p or miRNA negative control (Pre-miR-CTR) (d) for 72 h. GAPDH was used for normalization. e Quantification of miR-125a-5p level in the cells transfected with Pre-miR-125a-5p or Pre-miR-CTR was assessed by RT-qPCR. RNU6B was used for normalization. The bars indicate mean values of three independent replicates and error bars refer to standard deviation between replicates (n = 3). Statistical differences between the groups were calculated using paired student's t-test and P < 0.05 was considered significant. Evaluation of pFAK and FAK expressions in imatinib-sensitive parental GIST882 cells and imatinib-resistant GIST882R subclones. a Evaluation of KIT mutation and protein expressions of GIST markers in the imatinib-sensitive GIST882 and three independent imatinib-resistant subclones (GIST882-R1, GIST882-R2 and GIST882-R4). The chromatograms at the top show the KIT K642E mutation in GIST882 and GIST882R subclones. Photomicrographs below show expression of CD117, DOG1 and CD34 by immunocytochemistry (Magnification: 400 ×). b Validation of PTPN18 protein expression (upper) and miR-125a-5p (lower) in GIST882 and GIST882R cells using Western blot and RT-qPCR analyses, respectively. The PTPN18/GAPDH ratios are indicated below the Western blot images. c and d Western blot analyses of pFAK (c) and FAK (d) protein expression levels in GIST882 and GIST882R cells. GAPDH was used for normalization. Error bars refer to standard deviation of the mean (SD) from three independent experiments. Statistical differences between groups were calculated using unpaired student's t-test and P < 0.05 was considered significant. and treatment with FAKi reduced pFAK expression in both miR-125a-5p over-expressing and Pre-miR-CTR transfected cells (Fig. 4b) . Concordant with our previous observation [5] , cell viability of the miR125a-5p over-expressing cells was higher than the negative control (Pre-miR-CTR)-treated cells upon treatment with imatinib only (P = 0.006; Fig. 4c ). Treatment with FAKi enhanced imatinib-induced cell toxicity in the miR-125a-5p over-expressing cells, which was comparable to the effect in Pre-miR-CTR-treated cells (Fig. 4c) . The results indicate that FAKi could re-sensitize the resistant cells to imatinib mediated by miR-125a-5p over-expression.
Comparisons of pFAK and FAK levels with imatinib resistance, metastasis, KIT mutation status and overall survival in GIST patients
To investigate the association of FAK and pFAK expressions with imatinib resistance, we evaluated pFAK and FAK protein levels in 13 imatinib-resistant and 15 imatinib-sensitive GIST specimens using Western blot analysis ( Fig. 5a ; Table 1 ). As illustrated in Fig. 5b , pFAK levels were not significantly different between the imatinib-resistant and -sensitive samples (P = 0.821, Mann-Whitney U-test). However, FAK levels were higher in the imatinib-resistant as compared to imatinib-sensitive GISTs (P = 0.015, Mann-Whitney U-test; Fig. 5b ).
In our previous report [5] , we only observed the effect of miR-125a- 5p regulation on imatinib response in GIST882 cells harboring a single KIT mutation but not in GIST48 cells with double KIT mutations. We therefore sub-divided the imatinib-resistant GIST group according to single or double KIT mutations and compared their pFAK and FAK expression levels with the imatinib-sensitive group. Among the 13 imatinib-resistant GISTs, three tumors had a single KIT mutation, eight had double KIT mutations and the remaining two carried a PDGFRA mutation. Those PDGFRA mutated tumors were excluded in this analysis. We observed that the imatinib-resistant tumors with double KIT mutation had higher FAK, but not pFAK, level than the imatinib-sensitive tumors (P = 0.001), and no differences in FAK and pFAK expression were observed between the imatinib-sensitive and -resistant tumors with single KIT mutation (Fig. 5c ).
To determine associations of FAK and pFAK expression levels with imatinib resistance, metastasis and KIT mutation status, we compared tumors with high and low FAK or pFAK expression levels based on the median levels of all tumors analyzed. Although FAK and pFAK levels were not associated with imatinib resistance, their expression levels were associated with KIT mutation status (P = 0.039 for both FAK and pFAK; Table 1 ). High FAK level was associated with double KIT mutation, while high pFAK was associated with single KIT mutation. Additionally, we found that high FAK expression was associated with the group of patients who developed metastasis (P = 0.012; Table 1 ). On the other hand, patients with high expression of pFAK were found to have shorter overall survival (P = 0.028; log-rank test), whereas FAK expression was not statistically significant (Fig. 5d ).
Discussion
In this study, we sought to investigate the substrate of the PTPN18 tyrosine phosphatase that might have a role in imatinib resistance in GIST. We showed that PTPN18 and miR-125a-5p regulate pFAK expression level in GIST cells, and pFAK plays an important role in imatinib resistance of GIST.
Phosphorylation of FAK is regulated by PTPN18 and miR-125a-5p
We previously demonstrated that PTPN18 can modulate imatinib sensitivity in GIST cells [5] , however its specific target protein(s) is yet to be identified. To our knowledge, PTPN18 is only known to dephosphorylate the phospho-tyrosine residues of Src [14] and HER2 [6] . Herein, we speculated that pFAK might be the substrate of PTPN18 for two reasons. First, PTPN12, which belongs to the same protein tyrosine phosphatase as PTPN18, has been shown to dephosphorylate FAK [15] . Second, FAK or pFAK inhibition increases imatinib sensitivity in GIST cells [11] . Indeed, we observed increased expression of pFAK upon silencing of PTPN18, but the FAK level was unchanged, indicating that pFAK induction is specifically due to inhibition of the tyrosine phosphatase PTPN18. Additionally, over-expression of miR-125a-5p also increased pFAK expression, suggesting that pFAK is a downstream target of the miR-125a-5p/PTPN18 axis. Although pFAK expression is known to be higher in imatinib-resistant GIST [11] , it is still unknown how the expression is regulated. Here, we propose miR-125a-5p regulation as a mechanism for activation of FAK by phosphorylation in GIST. Tumors with KIT mutation (n = 23) Single (n = 12) 3 9 0.039 9 3 0.039 Double (n = 11) 8 3 3 8
Note: High and low refer to above and below the median protein expression level of all tumors. a P-values were determined by two-tailed Fisher's exact test. P < 0.05 are indicated in bold. Fig. 5 . Evaluation of pFAK and FAK expressions in GIST specimens and their relationship with imatinib response, mutation status, and survival. a pFAK and FAK protein expression levels were determined by Western blotting in 13 imatinib-resistant and 15 imatinib-sensitive GIST specimens. GAPDH was used for normalization. Two samples (GIST10-3 and GIST11) were analyzed twice as indicated by * and # . R and S refer to resistant and sensitive, respectively. b Quantification of pFAK (left) and FAK (right) protein expression levels in all imatinib-resistant and -sensitive samples regardless of mutation status by Western blot analysis. c Comparison of pFAK (left) and FAK (right) protein expression levels between imatinib-resistant samples according to their mutation status (single or double KIT) and imatinib-sensitive samples. Statistical differences between the two groups were calculated using Mann-Whitney U-test. One-way ANOVA was used to evaluate the significance of difference among the groups. P < 0.05 was considered significant. d Kaplan-Meier plots showing associations between high and low expression of pFAK (left) or FAK (right) and overall survival in 22 GIST patients. High or low expression levels refer to higher or lower than the median level of pFAK or FAK, respectively. Differences in survival were calculated by log-rank test.
pFAK is a potential therapeutic target in acquired imatinib-resistant GISTs
Here, we observed an increased expression of pFAK in the imatinibresistant GIST882R subclones compared to their imatinib-sensitive parental cells. The results are concordant with previous findings in another acquired imatinib-resistant GIST cell line, i.e. GIST-T1-R cells [11] , supporting that the effect is not cell line specific. Importantly, we (in this study) and Takahashi et al. [11] demonstrate that inhibition of FAK phosphorylation by FAK inhibitor increases imatinib sensitivity and induces apoptosis in imatinib-resistant GIST cell lines, supporting the important role of pFAK in imatinib resistance and its potential therapeutic target to overcome imatinib resistance in GISTs.
Several FAK inhibitors (such as GSK-2256098 from GlaxoSmithKline, VS-6063 and PF-00562271 from Pfizer) have been tested in phase I clinical trials, and they are generally well tolerated and safe in patients with advanced cancers [16] [17] [18] [19] . Although there are no FAKi clinical trials specifically for GIST, several clinical trials on combination therapies of FAKi and Pembrolizumab checkpoint inhibitor are ongoing for patients with advanced solid tumors (https://clinicaltrials. gov/).
Can FAK phosphorylation level predict imatinib response and survival in GIST?
In this study, we attempted to evaluate the clinical significance of pFAK in imatinib response. Given our previous observation of lower PTPN18 protein levels in imatinib-resistant GISTs and inverse correlation with miR-125a-5p levels [5] , we would expect a difference in pFAK levels between sensitive and resistant GISTs. However, in our previous study, we only observed the effect of miR-125a-5p regulation on imatinib response in the single KIT mutated GIST882 cells but not in the double KIT mutated GIST48 cells [5] , suggesting miR-125a-5p regulation of PTPN18 as an alternative mechanism in imatinib resistance. Here, we noted that two of the three imatinib-resistant GISTs with single KIT mutation (GIST3 and GIST4) seemed to have higher pFAK expression than the double KIT mutation tumors and the majority of imatinib-sensitive GISTs (Figs. 5a and 5c ). However the number of imatinib-resistant GISTs with single KIT mutation included in this study was too small for drawing any conclusion. Further investigations with larger sample sizes are warranted to determine whether pFAK could be a prognostic marker for imatinib response in GISTs with single KIT mutation. On the other hand, we observed that higher pFAK expression is associated with shorter overall survival in GIST. Similarly, high pFAK expression is also associated with aggressiveness and poor survival in several other cancer types, including osteosarcoma [20] , colorectal cancer [21] and gastric carcinomas [22] . Together, we propose that pFAK can be a prognostic marker in GIST, however further validations are needed.
FAK expression is associated with metastatic disease
Over-expression of FAK, but not pFAK, is associated with malignant behavior (increasing tumor size, mitotic rate and clinical risk) in GIST [9] . In line with previous findings, we also showed that elevated FAK expression is associated with metastasis in GISTs, suggesting an important role of FAK in tumor progression. FAK can drive tumor growth and metastasis through kinase-dependent or -independent functions [23] . Given that we, and others [9] , did not observe significant association of pFAK level with tumor progression, it is tempting to speculate that the involvement of FAK in tumor progression of GIST is kinaseindependent.
Conclusions
We identify pFAK as a novel target of PTPN18 that plays an important role in imatinib resistance of GIST, suggesting that pFAK may serve as a therapeutic target to overcome imatinib resistance in GIST.
